NanoBio Closes $11m Series C

Biopharmaceutical company NanoBio has closed an $11 million Series C financing. The company’s lead product candidates are treatments for herpes labialis, onychomycosis, vaginitis, cystic fibrosis and a broad platform of nanoemulsion-based vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

North AmericaUSBriefs